In its latest corporate financing, UK-quoted IP commercializer PureTech Health PLC has raised $100m for use advancing therapies within its stable of incubated affiliates and its own growing pipeline of proprietary assets, which CEO Daphne Zohar says "focus on cross-talk and biological processes associated with the brain-immune-gut interface."
In an interview with Scrip, Zohar said PureTech would use the placing to support its more advanced affiliates, such as...








